<DOC>
	<DOCNO>NCT01594918</DOCNO>
	<brief_summary>The purpose study test safety cabazitaxel , mitoxantrone , prednisone ( CAMP ) combination different dose level determine high dose cause bad side effect . The investigator want find effect , good and/or bad , CAMP patient metastatic castration-resistant prostate cancer .</brief_summary>
	<brief_title>Phase I Cabazitaxel , Mitoxantrone , Prednisone Metastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This Phase I , open label , dose-finding , multicenter clinical trial establish maximum tolerate dose ( MTD ) dose limit toxicity ( DLT ) cabazitaxel ( 25 mg/m2 IV q21 day ) combination mitoxantrone ( 4-12 mg/m2 IV q21 day ) prednisone ( 5mg orally BID ) patient metastatic CRPC undergone prior chemotherapy metastatic disease . Up five cohort enrol determine MTD DLT profile combination . An accelerated titration design method use order minimize number patient expose subtherapeutic dos mitoxantrone .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma prostate . 2 . Progressive metastatic prostate cancer ( positive bone scan measurable disease ) despite castrate level testosterone ( either orchiectomy LHRH agonist therapy ) . 3 . Patients may either nonmeasurable disease OR measurable disease 4 . All patient must PSA ≥ 2 ng/mL . 5 . Progressive disease base one following : 1. transaxial image 2. rise PSA 3. radionuclide bone scan Patients whose sole manifestation progression increase diseaserelated symptom eligible . 1 . For patient measurable disease , progression define RECIST criterion . 2 . For patient nonmeasurable disease , positive bone scan elevate PSA require . PSA evidence progressive prostate cancer firstline chemotherapy consist PSA level least 2 ng/ml rise least 2 successive occasion , least one week apart . If confirmatory PSA ( # 3 ) value le ( i.e. , # 3b ) screening PSA ( # 2 ) value , additional test rise PSA ( # 4 ) require document progression purpose eligibility . 3 . Radionuclide bone scan : new metastatic lesion 6 . Testosterone &lt; 50 ng/dL . Patients must continue primary androgen deprivation LHRH analogue undergone orchiectomy . 7 . ECOG Performance Status 0 2 . 8 . Required Laboratory value : 1 . Creatinine &lt; 1.5 x upper limit normal ( ULN ) . If Cr . &gt; 1.5 x ULN , calculate creatinine clearance &gt; 40cc/min . 2 . ALT AST within normal limit 3 . Absolute neutrophil count &gt; 2,000/mm3 4 . Platelets &gt; 100,000/ mm3 5 . Hemoglobin &gt; 8.0 gm/dL 6 . Total bilirubin within normal limit 9 . Ejection fraction MUGA scan echocardiogram ≥ low limit institutional normal . 10 . Patients receive hormonal therapy ( i.e . dose megestrol acetate ( Megace ) , Proscar ( finasteride ) , herbal product know decrease PSA level ( e.g. , Saw Palmetto PCSPES ) LHRH agonist/antagonist stable dose corticosteroid prior chemotherapy regimen must discontinue agent least 4 week prior enrollment . Progressive disease must document discontinuation hormonal therapy . 11 . No systemic therapy prostate cancer within 28 day prior initiation protocol . 12 . Prior radiation therapy complete ≥ 4 week prior enrollment . 13 . No history radiopharmaceutical ( strontium , samarium ) prostate cancer treatment . 14 . Patients must agree use adequate contraception ( hormonal barrier method birth control ) prior study entry , duration study participation 3 month discontinue therapy . Should patient 's sexual partner become pregnant suspect pregnant patient participate study , inform treat physician immediately . 15 . Life expectancy &gt; 12 week . 16 . Age ≥ 18 year 17 . Inclusion Minorities : Men member ethnic group eligible trial . 1 . Patients significant cardiovascular disease include congestive heart failure ( NYHA class III IV ) , active angina pectoris myocardial infarction within 6 month . 2 . Patients serious intercurrent infection , nonmalignant medical illness uncontrolled whose control may jeopardize complication therapy . 3 . Patients psychiatric illness/social situation would limit compliance study requirement . 4 . Patients preexist neuropathy great CTCAE Grade 1 ( motor sensory ) . 5 . Patients know prior severe hypersensitivity reaction cabazitaxel agent contain polysorbate 80 . 6 . Patients know active brain metastasis exclude poor prognosis . Head CT NOT routinely require prior enrollment . Patients treat , asymptomatic brain metastasis eligible enrollment . 7 . Patients `` currently active '' second malignancy nonmelanoma skin cancer exclude . [ Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . ] 8 . Concurrent use moderate strong CYP3A4 inhibitor allow .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>CRPC</keyword>
	<keyword>prostate</keyword>
	<keyword>CAMP</keyword>
</DOC>